Drug intelligence / Profile preview

OsteoStem

Development stage: Preclinical
Lead developer: Escape Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Injection

Overview

OsteoStem is an investigational cell therapy being developed by Escape Therapeutics for the treatment of acute fractures. The product consists of osteogenic progenitor cells, which are precursor cells committed to the bone-forming lineage. By delivering these cells to the site of injury, OsteoStem is intended to augment the body's innate regenerative capacity, promoting more efficient bone formation and structural repair. The program is currently in the preclinical stage of development, focusing on enhancing orthopedic healing where natural repair may be compromised.

Brand names: OsteoStem

Beyond the preview

Go deeper on OsteoStem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OsteoStem.

Explore the full profile